Early bladder cancer: Concept, diagnosis, and management

被引：31

作者：

Kitamura H. ^{[1
]}

Tsukamoto T. ^{[1
]}

机构：

[1] Department of Urology, Sapporo Medical University, School of Medicine, Chuo-ku, Sapporo 060-8543

来源：

International Journal of Clinical Oncology | 2006年 / 11卷 / 1期

关键词：

Bladder; Cancer; Progression; Recurrence; Treatment; Urine markers;

D O I：

10.1007/s10147-006-0552-y

中图分类号：

学科分类号：

摘要：

Recent evidence on molecular pathways helps us to understand the pathogenesis of bladder cancer. However, the molecular mechanisms of recurrence of the disease and progression into muscle-invasive disease are not fully understood. The diagnostic accuracy and specificity of innovative markers for detection of the disease currently available in the clinical setting are still far from the level where cystoscopy would not be needed. Although risk factors for progression to muscle-invasive disease have been identified, we still cannot predict accurately the clinical behavior of superficial bladder cancer. In this review article, we summarize recent evidence on molecular pathogenesis, risk factors for recurrence and progression, urine markers for detection, and treatments in superficial bladder cancer. © The Japan Society of Clinical Oncology 2006.

引用

页码：28 / 37

页数：9

共 96 条

[11]

Jebar A.H., Hurst C.D., Tomlinson D.C., Et al., FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial carcinoma, Oncogene, 24, pp. 5218-5225, (2005)

[12]

Orlow I., Larue H., Osman I., Et al., Deletions of the INK4A gene in superficial bladder tumors: Association with recurrence, Am J Pathol, 155, pp. 105-113, (1999)

[13]

Hartmann A., Zanardo L., Bocker-Edmonston T., Et al., Occurrence of chromosomal 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder, Cancer Res, 62, pp. 809-818, (2002)

[14]

Sidransky D., Frost P., Von Eschenbach A., Et al., Clonal origin of bladder cancer, N Engl J Med, 326, pp. 737-740, (1992)

[15]

Harris A.L., Neal D.E., Bladder cancer-field versus clonal origin, N Engl J Med, 326, pp. 443-447, (1992)

[16]

Hafner C., Knuechel R., Stoehr R., Hartmann A., Clonality of multifocal urothelial carcinomas: 10 years of molecular gnetic studies, Int J Cancer, 101, pp. 1-6, (2002)

[17]

Habuchi T., Origin of multifocal carcinomas of the bladder and upper urinary tract: Molecular analysis and clinical implications, Int J Urol, 12, pp. 709-716, (2005)

[18]

Sylvester R.J., Oosterlinck W., Van Der Meiden A.P.M., A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials, J Urol, 171, pp. 2186-2190, (2004)

[19]

Duggan B.J., Gray S.B., McKnight J.J., Oligoclonality in bladder cancer: The implication for molecular therapies, J Urol, 171, pp. 419-425, (2004)

[20]

Hinotsu S., Akaza H., Ohashi Y., Kotake T., Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection, Cancer (Phila), 86, pp. 1818-1826, (1999)

← 1 2 3 4 5 6 7 8 9 10 →